Huberman LabPsychedelics & Neurostimulation for Brain Rewiring | Dr. Nolan Williams
CHAPTERS
- 0:00 – 13:40
Introduction, Guest Background, and Episode Overview
Huberman introduces Dr. Nolan Williams, a psychiatrist and brain stimulation researcher at Stanford, outlining his work on depression, TMS, and combining neurostimulation with psychedelics. He previews discussion of ibogaine, psilocybin, MDMA, ketamine, and the future of circuit‑based treatments, then describes the new Huberman Lab premium channel and sponsor messages.
- •Dr. Nolan Williams runs Stanford’s Brain Stimulation Lab, focusing on depression and severe mood disorders.
- •His work is distinguished by combining TMS with psychedelics and neuroplasticity protocols.
- •The episode will cover drug histories, legality, safety in adults and children, and efforts to create non‑hallucinogenic analogues.
- •Huberman announces a paid premium AMA channel and clarifies the main podcast remains free.
- 13:40 – 28:20
Depression’s Burden and Brain–Heart Connections
Williams frames depression as the most disabling condition globally, a risk factor for heart disease, and a state that worsens other medical illnesses. He explains how specific prefrontal regions causally influence heart rate via the vagus nerve, and why focusing on these circuits reframes depression beyond vague mind‑heart metaphors.
- •Depression now recognized by the American Heart Association as a major coronary artery disease risk factor.
- •Moderate depression is about as disabling as an acute heart attack; severe depression akin to untreated, fatal cancer in disability.
- •Emergency psychiatric care paradox: as suicidal risk rises, available treatments and diagnostic tests often decrease.
- •TMS over left DLPFC produces a reproducible ~10 bpm heart‑rate deceleration via a defined prefrontal–vagal pathway.
- 28:20 – 48:20
Hemispheric Mood Balance and Autonomic Control
They explore lateralization of mood circuits: left DLPFC excitation is antidepressant, while right‑sided circuits are tied to mania. Williams describes how DLPFC stimulation serves as a marker of being in the correct autonomic–mood network, but heart‑rate change itself is not the antidepressant mechanism.
- •Lesion mapping shows depression‑causing strokes connect to left DLPFC; mania lesions to right DLPFC (Mike Fox’s work).
- •Exciting left or inhibiting right DLPFC reduces depression; exciting right DLPFC can reduce mania.
- •TMS‑evoked heart‑rate deceleration is specific to left DLPFC and replicable, but not sufficient to treat depression alone.
- •Beta‑blockers and general heart‑rate lowering do not reliably alleviate depression, underscoring the importance of specific circuits.
- 48:20 – 1:30:00
Prefrontal Cortex, Rules, and Cognitive Control in Depression
Williams and Huberman reframe prefrontal function as governing ‘rules’ or belief systems, illustrated by Stroop tasks and hypnotizability experiments. They link this to psychotherapy’s attempts to rewrite maladaptive rules and show how in depression, deeper emotional regions can overrun prefrontal governance.
- •DLPFC subregions connect to different parts of the anterior cingulate, influencing cognitive versus emotional control.
- •Inhibitory TMS to a specific DLPFC subregion can increase trait hypnotizability by altering cingulate connectivity.
- •Standard CBT for depression targets rigid, negative rules (e.g., ‘I am unlovable’), akin to rule‑switching in Stroop.
- •Williams’ data show that in responders to rapid TMS, temporal precedence flips: DLPFC activity comes before cingulate again.
- 1:30:00 – 1:48:20
Ketamine, Dissociation, and the Role of Opioid Receptors
The discussion shifts to ketamine’s antidepressant use and the debate over whether its dissociative state is necessary. Williams presents his naltrexone–ketamine study showing that opioid blockade abolishes the antidepressant response while leaving the subjective ‘trip’ intact, implying pharmacology and state both matter.
- •Ketamine is a dissociative anesthetic with growing psychiatric use; dissociation correlates with but is not sufficient for benefit.
- •In a crossover study, 50 mg naltrexone blocked ketamine’s antidepressant effect without altering dissociation.
- •This challenges the notion that any psychedelic‑like subjective state alone can produce antidepressant effects regardless of underlying pharmacology.
- •Opioid mechanisms may also be implicated in TMS analgesia, as naloxone blocks TMS’s anti‑pain effects in some studies.
- 1:48:20 – 2:08:20
SSRIs, Serotonin, and the Shift to Circuit‑Based Psychiatry
Williams addresses recent controversy over serotonin and SSRIs, emphasizing that while SSRIs work for many, they likely do so via circuit‑level plasticity rather than correcting a simple chemical deficit. He lays out a progression from psychoanalytic ‘psychiatry 1.0’ through ‘chemical imbalance 2.0’ to ‘circuit‑based 3.0.’
- •SSRIs have robust evidence for efficacy in subsets of patients across depression, anxiety, and OCD.
- •Their delayed onset and broad action suggest changes in BDNF and plasticity, not acute serotonin replenishment, drive benefits.
- •Recent meta‑analyses show no simple serotonin–depression deficit, but this doesn’t negate SSRI efficacy.
- •Circuit‑based psychiatry reframes depression as reversible network dysregulation (e.g., DLPFC–subgenual cingulate connectivity) rather than permanent chemical or childhood damage.
- 2:08:20 – 2:28:20
MDMA and Psilocybin for PTSD and Depression
They review clinical trial data on MDMA for PTSD and psilocybin for depression, including effect sizes, durability, and safety concerns. Williams also revisits the infamous but flawed MDMA neurotoxicity study and more recent evidence showing no clear long‑term cognitive harm in controlled MDMA users.
- •Phase 3 MDMA‑assisted psychotherapy trials show roughly two‑thirds of participants achieving clinically significant PTSD relief, often durable for years.
- •Open‑label psilocybin studies report 50–66% remission or major improvement in depression; randomized data show ~one‑third robust responders.
- •Follow‑up studies in pure MDMA users (e.g., LDS cohort using only MDMA) show no cognitive deficits compared to matched controls.
- •Subjective states include heightened emotional engagement (psilocybin) and empathogenic openness (MDMA), but underlying circuit changes are key.
- 2:28:20 – 2:51:40
Mechanisms of Psilocybin and the Importance of “Letting Go”
Williams outlines psilocybin’s serotonergic 5‑HT2A actions and its effects on brain connectivity, including increased global integration and reduced coupling between negative mood and self networks. They relate the therapeutic process to exposure and response prevention, emphasizing the therapeutic importance of surrendering control during sessions.
- •Neuroimaging shows psilocybin globally alters connectivity and decreases small‑world modularity; activity often decreases rather than increases overall.
- •Successful psilocybin treatment, like SAINT TMS, reduces connectivity between the subgenual cingulate and the default mode network.
- •Therapeutic ‘letting go’ resembles high‑intensity exposure therapy: patients revisit trauma or rigid beliefs without engaging usual avoidance responses.
- •Guides focus on safety and gentle encouragement rather than directive psychotherapy during acute psychedelic effects.
- 2:51:40 – 3:21:40
Ibogaine, 5‑MeO‑DMT, and Special Operations Veterans
The conversation moves to ibogaine, a long‑acting, non‑visual psychedelic used sacramentally in Gabon and now experimentally in special operations veterans. Williams describes life‑review experiences, moral injury repair, and an ongoing, deeply phenotyped Stanford study, along with follow‑on 5‑MeO‑DMT sessions.
- •Ibogaine is an alkaloid from Tabernanthe iboga root bark used in Bwiti ceremonies; it generates intense closed‑eye life reviews lasting 24–36 hours.
- •It is not recreational; participants often describe it as ‘10 years of psychotherapy in a night.’
- •Cardiac risk (QT prolongation) demands careful ECG screening, but Williams’ cohort has had no cardiac events under protocol.
- •Special operations veterans report relief from PTSD, TBI‑related symptoms, and moral injury, often describing self‑forgiveness and restored function.
- •5‑MeO‑DMT from Sonoran toads is administered in a separate session about a month later; its effects are shorter but intense.
- 3:21:40 – 3:51:40
Ayahuasca, Recidivism, and Cannabis Nuance
Williams explains how ayahuasca combines DMT with a reversible MAOI to make oral DMT psychoactive and notes its safety profile and unusual Brazilian prison recidivism findings. He then dissects cannabis into THC vs. CBD effects, highlighting pro‑psychotic risk of high‑THC use in youth and therapeutic potential of CBD.
- •Ayahuasca’s two‑plant brew (DMT + MAOI) is a remarkably precise pharmacologic combination discovered by Amazonian peoples.
- •Epidemiologic and small controlled studies suggest ayahuasca can reduce depression and may lower prison recidivism in Brazilian inmates.
- •CBD is anti‑epileptic and possibly anti‑psychotic; GW Pharmaceuticals has data in Dravet and Lennox‑Gastaut syndromes.
- •Modern high‑THC cannabis, especially in adolescence, is associated with increased psychosis risk; CBD has opposite effects.
- •Cannabis should be thought of as multiple drugs (THC, CBD, ratios), not a monolith.
- 3:51:40 – 4:15:00
Alcohol, Relative Drug Harms, and Future Reassessment
Using David Nutt’s comparative harm framework, Williams and Huberman discuss alcohol as the most harmful drug overall, surpassing heroin and cocaine when considering societal and individual damage. They predict a future where medicine treats alcohol more like smoking is treated today.
- •Nutt’s Lancet analysis ranks alcohol highest in combined personal and societal harm, ahead of heroin and crack cocaine.
- •Psilocybin sits near the low‑harm end of the spectrum, while cannabis is mid‑range and ketamine/MDMA somewhat lower than many assume.
- •Alcohol is normalized at universities and hospitals despite clear links to multiple cancers, accidents, violence, and poor decisions.
- •Williams predicts that, as with smoking, medicine will eventually eliminate alcohol from institutional culture.
- 4:15:00 – 4:33:00
Sleep Deprivation, Circadian Tools, and Mood
They address the paradoxical antidepressant effect of acute sleep deprivation and a ‘triple therapy’ that combines it with circadian phase shifts and bright light to create a more durable response. Williams cautions that while powerful, this must be medically supervised, and for most people, consistent sleep and light timing is the key leverage.
- •Single‑night sleep deprivation can transiently improve depression but benefit disappears after the next normal sleep.
- •Triple therapy (sleep deprivation + phase shift + bright light) can produce more durable antidepressant effects, but protocol is complex and pro‑anxiety if misapplied.
- •CBT‑I strategies (bed for sleep/sex only, light management, device control) are central non‑pharmacologic tools.
- •For mild depression, behavioral interventions (sleep, light, exercise, meditation) can be highly effective below a certain severity threshold.
- 4:33:00 – 5:11:40
SAINT/SNT: Accelerated TMS as a Breakthrough Depression Treatment
Williams lays out the history of TMS from crude ruler‑based targeting to highly individualized, MRI‑guided SAINT/SNT protocols. By using spaced‑learning principles and theta‑burst patterns, his team compresses months of stimulation into five days and achieves rapid, high remission rates in severe, treatment‑resistant depression.
- •Classic TMS emerged from combining knowledge of hypoactive prefrontal cortex in depression with evidence that repetitive TMS can increase cortical excitability (thumb motor maps).
- •Theta‑burst stimulation, mimicking hippocampal rhythms, can change cortical excitability for about an hour after a 40–180 second train.
- •SAINT/SNT uses resting‑state fMRI to pinpoint each person’s DLPFC region most anti‑correlated with subgenual cingulate, then applies 10 sessions/day for 5 days, spaced hourly.
- •Compared to standard six‑week protocols, SAINT delivers ~5x the dose in one week; 60–90% of highly treatment‑resistant patients remit.
- •The protocol is now FDA‑cleared via Magnus Medical, with multi‑site trials recruiting; Stanford’s BSL helps route interested patients to appropriate sites.
- 5:11:40
Closing Reflections and How to Access Trials
Huberman and Williams close by reflecting on destigmatizing psychiatric symptoms, the promise of circuit‑based treatments, and the importance of carefully controlled psychedelic and neuromodulation research. Huberman provides links to Williams’ lab for clinical trial participation and reiterates ways to support and learn from the Huberman Lab ecosystem.
- •Mild compulsive or depressive traits exist on a spectrum; disorders are defined by functional impairment, not symptom presence alone.
- •Patients often describe a newfound confidence after TMS or psychedelic‑assisted therapy that suicidal depression is reversible, which itself is protective.
- •Interested individuals can learn about and apply for Brain Stimulation Lab trials at bsl.stanford.edu.
- •Huberman summarizes resources: newsletters, premium AMA channel, Momentous supplements partnership, and social media for science education.
